UNSPSC 51142553: Lazabemide monohydrochloride

This classification denotes a monoamine oxidase inhibitor with the molecular formula C8H10ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PI150J9ZX1, chemically known as n-(2-aminoethyl)-5-chloro-2-pyridine-carboxamide hydrochloride, but more generally known as lazabemide monohydrochloride, which bears US NIH Compound Identifier 163727. European Medicines Agency schedules lazabemide monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08418MIG.

Most nations, for tariff purposes, schedule lazabemide monohydrochloride under HS 29333999. SMILES: C1CC(NCC1CL)C(=O)NCCN.CL.

UNSPSC 51142553 Lazabemide monohydrochloride is a Commodity code that does not align with recent state and local procurement activity in the available opportunities. The three most recent solicitations tagged under or near this code all address different pharmaceutical categories: naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products. None of these opportunities concern lazabemide monohydrochloride specifically, suggesting the code sees little or no relevant recent state and local purchasing activity.

The mismatch between the code's specific pharmaceutical scope and the actual buying patterns in recent opportunities indicates that state and local agencies are procuring naloxone and generic pharmaceuticals through broader competitive processes, but there is no evidence of current demand for lazabemide monohydrochloride under this Commodity code. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems; the Texas Health and Human Services Commission posted an RFI in April 2026 on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products. Unless the code receives renewed attention in upcoming solicitations or becomes tagged to actual lazabemide demand at state health agencies or correctional systems, this category presents minimal pursuit opportunity in the current market.